Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.
DONATE
Join The Academy as Dr. Jaime Rubin, Vice Chair for Investigator Development at Columbia University, addresses relevant topics and skills required for successful funding and grantsmanship.
This symposium presents a remarkable opportunity to convene with other researchers, clinicians, and industry leaders to discuss the extraordinary progress and immense potential of new drug therapies and technologies in paving the way for a brighter future in cancer treatment.
Scientists working in basic, translational, and clinical cancer metabolism research are invited to join the Academy in New York on April 17th to discuss the intersection between cell signaling and metabolism.
Join The Academy as Dr. Jaime Rubin, Vice Chair for Investigator Development at Columbia University, addresses relevant topics and skills required for successful funding and grantsmanship.
The Leon Levy Scholarships in Neuroscience (LLSN) aim to promote groundbreaking neuroscience research in the five boroughs of New York City. The scholarships support the most innovative young researchers at a critical stage of their careers—their postdoctoral research—as they develop the new ideas and directions that will help establish them as independent neuroscientists.
As the New York Academy of Sciences continues into its third century, Nicholas Dirks is at the helm of an extraordinary organization with a talented staff, a global community of more than 20,000 Members, and a network of top-echelon leaders in science, industry, academia, government and public policy. Bringing all these people together, the Academy is taking on COVID-19 and other world-wide challenges with the best solutions that science, technology, and bright minds can offer.
Available via
WEBINAR
Monday, May 15, 2017 - Wednesday, May 17, 2017
The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York
The treatment for myasthenia gravis (MG) — a rare, acquired autoimmune syndrome resulting in severe muscle weakness and fatigue, significant disability, and decreased life expectancy — has improved dramatically in the last several decades. While modern medical advances have reduced MG mortality rates over the last several decades, there has been an increase in reported cases especially among the aging population. The number of diagnosed MG cases is expected to rise as the aging population increases and screening techniques for MG improve. From a public health perspective it is clear that increased understanding of the etiology underlying MG is critical for enhancing diagnosis and treatment of this disease. To better translate basic research discoveries into the standard treatment regimen of MG patients, the New York Academy of Sciences, in partnership with the Myasthenia Gravis Foundation of America, will organize the 13th International Conference on Myasthenia Gravis and Related Disorders.
The conference will provide a forum for basic scientists and clinical researchers to discuss, disseminate, and highlight the advances and challenges of therapies for myasthenia gravis. The goals of this program are to: 1) provide a forum for basic, translational, and clinical researchers from academia and industry to present and discuss the most up-to-date findings in MG research; 2) explore and encourage multidisciplinary and multi-sector collaborations to enhance investigative approaches into MG and related autoimmune and neuromuscular disorders; 3) review current MG therapeutic options, ongoing clinical trials, and challenges and limitations faced in the clinic; and 4) identify knowledge gaps and future directions of research required for further breakthroughs. Ten plenary sessions will span the full spectrum of research from bench to bedside, including structure and function of the neuromuscular junction, advances in immunology, recent clinical developments related to MG, outcome measurements, clinical trial development, animal models of neuromuscular disease, MG treatment updates, congenital and Lambert-Eaton myasthenic syndromes, thymectomy, and the MGTX trial.
| By 04/03/2017 | After 04/03/2017 | Onsite | |
| Member | $650 | $700 | $750 |
| Member (Student / Postdoc) | $400 | $425 | $450 |
| Nonmember (Academia) | $800 | $850 | $900 |
| Nonmember (Corporate) | $950 | $1050 | $1150 |
| Nonmember (Non-profit) | $800 | $850 | $900 |
| Nonmember (Student / Postdoc / Fellow) | $450 | $475 | $500 |
Registration includes a complimentary, one-year Membership to the New York Academy of Sciences. Complimentary Memberships are provided to non-members only and cannot be used to renew or extend existing or expiring Memberships. A welcome email will be sent upon registration which will include your Membership credentials.
The three days' events also will be broadcast as webinars; registration is required. Membership is not included with webinar registration.
Please note: Transmission of presentations via the webinar is subject to individual consent by the speakers. Therefore, we cannot guarantee that every speaker's presentation will be broadcast in full via the webinar. To access all speakers' presentations in full, we invite you to attend the live event in New York City where possible.
| By 04/03/2017 | After 04/03/2017 | |
| Member | $100 | $115 |
| Member (Student / Postdoc) | $60 | $70 |
| Nonmember (Academia) | $125 | $140 |
| Nonmember (Corporate) | $150 | $165 |
| Nonmember (Non-profit) | $125 | $140 |
| Nonmember (Student / Postdoc / Fellow) | $70 | $85 |
| By 04/03/2017 | After 04/03/2017 | |
| Member | $255 | $295 |
| Member (Student / Postdoc) | $150 | $180 |
| Nonmember (Academia) | $320 | $360 |
| Nonmember (Corporate) | $385 | $420 |
| Nonmember (Non-profit) | $320 | $360 |
| Nonmember (Student / Postdoc / Fellow) | $180 | $215 |
For sponsorship opportunities please contact Alison Carley, PhD, at acarley@nyas.org or 212.298.8641.
 |  |
American Neurological Association
Muscular Dystrophy Association
The Myasthenia Gravis Association of Queensland
* Presentation times are subject to change.
Monday, May 15, 2017 | |
7:30 AM | Breakfast |
8:30 AM | Welcome and Introductions |
Session 1: Neuromuscular Junction (NMJ) Structure and FunctionSession Chair: Clarke R. Slater, PhD, Newcastle University, United Kingdom | |
8:55 AM | Functional Organization of the Neuromuscular Junction: Introduction |
9:05 AM | Presynaptic Plasticity in Myasthenia Gravis |
9:25 AM | More Than a Pretzel: Spatial Distribution of the Neuromuscular Junction Components |
9:45 AM | Molecular Mechanisms of the Formation of Neuromuscular Junction |
10:05 AM | Is Age-Related Neuromuscular Junction Fragmentation a Sign of Altered Neuromuscular Junction Function? |
10:25 AM | Networking Coffee Break |
Session 2: Congenital Myasthenic SyndromesSession Chair: Andrew G. Engel, MD, Mayo Clinic | |
10:55 AM | Presynaptic Congenital Myasthenic Syndromes Caused by Mutations in SNAP25B and MUNC13-1 |
11:15 AM | The Pathophysiological Mechanisms of CMS with Acetylcholinesterase Deficiency |
11:35 AM | Congenital Myasthenic Syndromes with Predominant Limb Girdle Weakness |
11:55 AM | Myasthenic Syndromes Due to Defects in COL13A1 and the N-Linked Glycosylation Pathway |
12:15 PM | Therapeutic Strategies for Congenital Myasthenic Syndromes |
12:35 PM | Networking Lunch |
Session 3: Thymus in Myasthenia GravisSession Chair: Rozen le Panse, PhD, INSERM, France | |
2:25 PM | Thymus Involvement in Myasthenia Gravis |
2:35 PM | MGTX Histopathology Findings |
2:55 PM | Toll-like Receptors 7 and 9 in Myasthenia Gravis Thymus |
3:15 PM | Networking Coffee Break |
Session 4: Serological Phenotypes and Unique Treatment ResponsesSession Chair: Angela Vincent, MSc, University of Oxford, United Kingdom | |
3:45 PM | Overview of Serological Classification of Myasthenia Gravis |
4:05 PM | Cortactin Antibodies in Myasthenia Gravis |
4:25 PM | MuSK Myasthenia Gravis |
4:45 PM | A Unique Sub-Phenotype of Myasthenia Gravis |
5:05 PM | Autoantibodies to Agrin in Myasthenia Gravis |
5:25 PM | Day 1 Closing Remarks |
6:00 PM | Day 1 Poster Session and Networking Reception (Marriott Downtown) |
8:30 PM | Day 1 Adjourns |
Tuesday, May 16, 2017 | |
7:15 AM | Sponsored Breakfast Session |
Session 5: Mechanisms of Autoimmunity (basic, including diseases other than Myasthenia Gravis)Session Chair: Sonia Berrih-Aknin, DSc, INSERM, France | |
8:30 AM | Introduction to Autoimmunity |
8:40 AM | Keynote Address: T cell Function in Autoimmunity |
9:10 AM | Regulatory B cells in Health and Disease |
9:30 AM | Estrogen-Mediated Downregulation of AIRE Influences the Gender-Bias in Autoimmune Diseases |
9:50 AM | Expanding Field of IgG4 Autoimmune Diseases |
10:10 AM | Networking Coffee Break |
Session 6: Mechanisms of Myasthenia Gravis Autoimmunity — UpdatesSession Chair: Kevin C. O'Connor, PhD, Yale School of Medicine | |
10:40 AM | Introduction to Myasthenia Gravis Autoimmunity |
10:50 AM | Mechanisms of B Cell and T Cell Immunopathology in Myasthenia Gravis |
11:10 AM | Immune Checkpoint Markers in Myasthenia Gravis Patients |
11:30 PM | Cytokine Production in Myasthenia Gravis Patients |
11:50 AM | Circulating MicroRNAs in Myasthenia Gravis |
12:10 PM | Networking Lunch |
Session 7: Day 2 Hot Topic Short Talks (Selected from Submitted Abstracts)Session Chair: To Be Announced | |
1:55 PM | Speaker to Be Announced |
2:05 PM | Speaker to Be Announced |
2:15 PM | Speaker to Be Announced |
2:25 PM | Speaker to Be Announced |
Session 8: Clinical Trials UpdateSession Chair: Henry Kaminski, MD, George Washington University | |
2:35 PM | Clinical Trials for Myasthenia Gravis |
2:45 PM | Eculizumab Results in Improvement in Activities of Daily Living and Muscle Strength in Refractory Generalized Myasthenia Gravis Patients Compared with Placebo |
3:05 PM | MGTX Primary and Secondary Outcomes |
3:25 PM | A Phase 1b Clinical Trial of CV-MG01, Acetylcholine Receptor Mimetic Peptides |
3:45 PM | Networking Coffee Break |
Session 9: Upcoming, Ongoing or Future Trials in Myasthenia GravisSession Chair: Jeffrey Guptill, MD, Duke University | |
4:15 PM | Overview Introduction |
4:25 PM | B Cell Targeted Treatment in Myasthenia Gravis (BeatMG): A Phase 2 Trial of Rituximab in Myasthenia Gravis |
4:45 PM | AChR-Specific Immunosuppressive Therapy of Myasthenia Gravis |
5:05 PM | Difficulty with Clinical Trials — What We Have Learned So Far? |
5:25 PM | Myasthenia Gravis Foundation of America Philanthropist of the Year Award Presentation: Honoring Mona Roth |
5:40 PM | Day 2 Networking Reception |
7:00 PM | Day 2 Adjourns |
Wednesday, May 17, 2017 | |
7:30 AM | Breakfast |
Session 10: Acetylcholine Receptor Animal ModelsSession Chair: Linda L. Kusner, PhD, George Washington University | |
8:30 AM | Acetylcholine Receptor Animal Models and Complement |
8:50 AM | Pathogenic Mechanisms and Treatment Strategies for AChR-MG in Preclinical Models |
9:10 AM | Toll-like Receptor (TLR) Agonists to Induce Experimental Autoimmune Myasthenia Gravis (EAMG) |
9:30 AM | Electrophysiology of Myasthenia Gravis Animal Models |
9:50 AM | Networking Coffee Break |
Session 11: Other Animal Models in Myasthenia GravisSession Chair: William Donald Phillips, PhD, University of Sydney, Australia | |
10:20 AM | Does Anti-MuSK Cause Myasthenia Simply by Inhibiting Agrin/MuSK Signaling? |
10:40 AM | Anti-MuSK IgG4 in the Passive Transfer Model |
11:00 AM | Experimental Studies on Seronegative Myasthenia |
11:20 AM | Using the Mouse Passive Transfer Model of Lambert–Eaton Myasthenic Syndrome (LEMS) to Explore Disease Pathology and Test New Therapeutic Leads |
11:40 AM | Lrp4 and Agrin Antibodies in Myasthenia Gravis |
12:00 PM | Remembering Claudio Mazia, MD, University of Buenos Aires, Argentina |
12:10 PM | Networking Luncheon |
Session 12: Day 3 Hot Topic Short Talks (Selected from Submitted Abstracts)Session Chair: To Be Announced | |
1:25 PM | Speaker to Be Announced |
1:35 PM | Speaker to Be Announced |
1:45 PM | Speaker to Be Announced |
1:55 PM | Speaker to Be Announced |
2:05 PM | Speaker to Be Announced |
2:15 PM | Networking Coffee Break |
Session 13: Treatment Guidelines from Around the WorldSession Chair: Donald B. Sanders, MD, Duke University Medical Center | |
2:45 PM | International Consensus Guidance Statements for Myasthenia Gravis Treatment |
3:15 PM | Treatment Guidelines for Myasthenia Gravis in Japan |
3:35 PM | The Myasthenia Gravis Guidelines of the Association of British Neurologists |
3:55 PM | Unique Treatment Challenges in South America |
4:15 PM | Panel Discussion: Comparing and Contrasting Treatment Strategies around the World |
4:45 PM | Closing Remarks |
4:50 PM | Meeting Concludes |
University of Virginia
George Washington University
website
INSERM
website
The New York Academy of Sciences
University of Toronto
Southern General Hospital, United Kingdom
The New York Academy of Sciences
Duke University Medical Center
website
George Washington University
website
Myasthenia Gravis Foundation of America
University of Sydney
website
Case Western Reserve University School of Medicine
Hanamaki General Hospital, Japan
Leiden University Medical Center, The Netherlands
website
University of Oxford, United Kingdom
website
Myasthenia Gravis Foundation of America
University of Buffalo
website
University of Oxford
website
University of Miami
INSERM
website
Foundation Neurological Institute "Carlo Besta"
Institute of Myology, France
Mayo Clinic
Catholic University, Italy
website
Duke University Medical Center
website
University of Cape Town
website
University of North Carolina at Chapel Hill
Leiden University Medical Center, The Netherlands
Universitat Autonoma de Barcelona
George Washington University
Harvard Institutes of Medicine
George Washington University
website
INSERM, France
website
Université Paris Descartes
website
University of Pennsylvania
Newcastle University, United Kingdom
Maastricht University, The Netherlands
website
University of Heidelberg
University College London, United Kingdom
website
Augusta University
website
Universitätsklinikum Erlangen, Germany
Antwerp University Hospital
website
University of Pittsburgh
website
International University of Health and Welfare, Japan
Yale University School of Medicine
Yale School of Medicine
website
John Radcliffe Hospital
University of Sydney
website
Leiden University Medical Center, The Netherlands
website
Nencki Institute of Experimental Biology, Poland
website
Uppsala University, Sweden
website
Wright State University
website
University of Basel, Switzerland
website
Alfredo Lanari Institute of Medical Investigations, University of Buenos Aires, Argentina
Duke University Medical Center
website
Newcastle University, United Kingdom
website
Greater Manchester Neuroscience Centre, United Kingdom
Leiden University Medical Center, The Netherlands
website
University of Oxford, United Kingdom
website
University of Buffalo
website
Duke University Medical Center
website
Istanbul University
website